Industry Collaboration Group member since 2012
Professor of Medicine, Microbiology and Immunology, UNC School of Medicine and Director, UNC HIV Cure Center
University of North Carolina at Chapel Hill
David Margolis’s laboratory has a long history of translational HIV research, investigating basic molecular, virological and immunological phenomenon and leveraging insights to develop new interventions in HIV disease. His work has involved many aspects of HIV science and medicine. For the past two decades, a central focus has been the study of molecular mechanisms of HIV proviral latency and persistence despite potent antiretroviral therapy. David and his team have begun to define the role of epigenetic factors in the restriction of HIV expression, and this has led to diverse, multidisciplinary collaborations and translational clinical studies resulting in discovery and high-impact work. He is the principal investigator for the Collaboratory of AIDS Researchers for Eradication (CARE), an NIH-funded research organization that seeks to develop the tools to bring an HIV cure from the bench to the clinic.
He is also the principal investigator of two NIH-funded studies to combine biologics (broadly neutralizing antibodies or antiviral T-cell infusions) and small-molecule anti-latency agent (HDAC inhibitor) in FDA-approved investigations to attempt to precisely document the depletion of persistent HIV infection. Finally, he directs the University of North Carolina at Chapel Hill HIV Cure Center, created to support novel and impactful research needed to advance towards therapies to induce an HIV remission. It currently supports seven junior faculty scientists in a multidisciplinary environment ideal for training and translational research.